We provide you with 20 years of free, institutional-grade data for PSNL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PSNL. Explore the full financial landscape of PSNL stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about PSNL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Personalis, Inc(NASDAQ:PSNL) 
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies. It offers NeXT Platform, which provides data for cancer therapy development, personalized therapies, therapy selection, and dia...
Website: http://www.personalis.com
Founded: 2011
IPO Price: $17 (Jun 20, 2019)
Full Time Employees: 181
CEO: John S. West
Sector: Healthcare
Industry: Diagnostics & Research